### Highlights of This Issue 3359

#### SPECIAL FEATURES

**CCR Translations**

- **3361** MET as a Target in Papillary Renal Cell Carcinoma
  Andre P. Fay, Sabina Signoretti, and Toni K. Choueiri
  See related article, p. 3411

**CCR Perspectives in Drug Approval**

- **3364** U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009
  Sonia K. Morgan-Linnell, David J. Stewart, and Razelle Kurzrock

**Statistics in Clinical Cancer Research**

- **3371** Blocking and Randomization to Improve Molecular Biomarker Discovery
  Li-Xuan Qin, Qin Zhou, Faina Bogomolniy, Liliana Villafania, Narciso Olvera, Magali Cavatore, Jaya M. Satagopan, Colin B. Begg, and Douglas A. Levine

**Molecular Pathways**

- **3379** Molecular Pathways: CDK4 Inhibitors for Cancer Therapy
  Mark A. Dickson

- **3384** Molecular Pathways: Niches in Metastatic Dormancy
  Kenji Yumoto, Matthew R. Eber, Janice E. Berry, Russell S. Taichman, and Yusuke Shiozawa

**Review**

- **3390** Infusions of Allogeneic Natural Killer Cells as Cancer Therapy
  Wing Leung

### HUMAN CANCER BIOLOGY

- **3401** Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions
  Yong-Chen Lu, Xin Yao, Jessica S. Crystal, Yong F. Li, Mona El-Gamil, Colin Gross, Lindy Davis, Mark E. Dudley, James C. Yang, Yardena Samuels, Steven A. Rosenberg, and Paul F. Robbins

- **3411** MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array
  Laurence Albige, Justine Guegan, Audrey Le Formal, Virginie Verkarre, Nathalie Rioux-Leclercq, Mathilde Sibony, Jean-Christophe Bernhard, Philippe Camargo, Zahra Merabet, Vincent Molinie, Yves Allory, Cedric Orear, Sophie Couvé, Sophie Gad, Jean-Jacques Patard, and Bernard Escudier
  See related article, p. 3361

- **3422** Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer
  Natalie Hartmann, Nathalia A. Giese, Thomas Giese, Isabel Poschke, Rienk Oftringa, Jens Werner, and Eduard Ryschich

- **3434** Overexpression of Sirt7 Exhibits Oncogenic Property and Serves as a Prognostic Factor in Colorectal Cancer
  Hongyan Yu, Wen Ye, Jiangxue Wu, Xiangqi Meng, Ran-yi Liu, Xiaofang Ying, Yi Zhou, Hui Wang, Changchuan Pan, and Wenlin Huang

### CANCER THERAPY: PRECLINICAL

- **3446** Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
  Mohammad Atefi, Earl Avramis, Amanda Lassen, Deborah J.L. Wong, Lidia Robert, David Foulad, Michael Cerniglia, Bjorn Titz, Thinle Chodon, Thomas G. Graeber, Begonya Comin-Anduix, and Antoni Ribas
Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma
Ian Judson, Michelle Scurr, Kate Gardner, Elizabeth Barquin, Marcelo Marotti, Barbara Collins, Helen Young, Juliane M. Jürgensmeier, and Michael Leahy

Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR Mutations
Mikihiro Kohno, Tatsuro Okamoto, Kenichi Suda, Mototsugu Shimokawa, Hirokazu Kitahara, Shinichiro Shimamatsu, Hideyuki Konishi, Tsukihisa Yoshida, Mitsuhiro Takenoyama, Tokuiro Yano, and Yoshiko Maehara

SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Letter
Abolfazl Avan, Mina Maftouh, Amir Avan, Carmelo Tibaldi, Paolo A. Zucali, and Elisa Giovannetti

SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Response
Qianxia Li, Huihua Xiong, and Xianglin Yuan

 ABOUT THE COVER

Loss of S6 phosphorylation as a biomarker of response to PI3K/mTOR pathway inhibition. The representative image shows immunohistochemical staining for phosphorylated S6 protein (ser235-236) in SUM190 breast cancer cell line xenografts treated with the pan-PI3K inhibitor BKM120. For details, see the article by O’Brien and colleagues on page 3507 of this issue.